Recent Advances in IRAK1: Pharmacological and Therapeutic Aspectsopen access
- Authors
- Kim, Kyeong Min; Hwang, Na-Hee; Hyun, Ja-Shil; Shin, Dongyun
- Issue Date
- May-2024
- Publisher
- MDPI
- Keywords
- interleukin receptor-associated kinase (IRAK) proteins; inhibitor; degrader; immunity
- Citation
- MOLECULES, v.29, no.10
- Journal Title
- MOLECULES
- Volume
- 29
- Number
- 10
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/91732
- DOI
- 10.3390/molecules29102226
- ISSN
- 1420-3049
1420-3049
- Abstract
- Interleukin receptor-associated kinase (IRAK) proteins are pivotal in interleukin-1 and Toll-like receptor-mediated signaling pathways. They play essential roles in innate immunity and inflammation. This review analyzes and discusses the physiological functions of IRAK1 and its associated diseases. IRAK1 is involved in a wide range of diseases such as dry eye, which highlights its potential as a therapeutic target under various conditions. Various IRAK1 inhibitors, including Pacritinib and Rosoxacin, show therapeutic potential against malignancies and inflammatory diseases. The covalent IRAK1 inhibitor JH-X-119-01 shows promise in B-cell lymphomas, emphasizing the significance of covalent bonds in its activity. Additionally, the emergence of selective IRAK1 degraders, such as JNJ-101, provides a novel strategy by targeting the scaffolding function of IRAK1. Thus, the evolving landscape of IRAK1-targeted approaches provides promising avenues for increasingly safe and effective therapeutic interventions for various diseases.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - ETC > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/91732)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.